奥氮平所致代谢综合征与血清IL-6水平及认知功能的关系

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (605 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the relationship between metabolic syndrome (MS) caused by Olanzapine and serum interleukin-6 (IL-6) levels and cognitive function. Methods From January 2015 to December 2017, a total of 242 cases who were treated with Schizophrenia for more than two years of single-drug use were recruited at Shanghai Mental Health Center of Shanghai Jiao Tong University School of Medicine, Yuebei Third People′s Hospital, Jinhua Second Hospital, and Wenzhou Kangning Hospital in Zhejiang Province. According to whether they were associated with MS, they were divided into 105 cases in MS group and 137 cases in non-MS group. The positive and negative symptom scale (PANSS) was used to assess the clinical symptoms of patients with schizophrenia, while the repeatable battery for the assessment of neuropsychological status (RBANS) was used to assess cognitive function, and the serum IL-6 levels were measured by enzyme-linked immunosorbent assay. Results There were highly statistically significant differences in the use time and dose of Olanzapine between the two groups (P ＜ 0.01). The score of PANSS negative symptoms in the MS group was higher than that in the non-MS group, and the difference was statistically significant (P ＜ 0.05). The RBANS immediate memory, attention, delayed memory and total scores of the MS group were lower than those of the non-MS group, and the differences were statistically significant (P ＜ 0.05). The level of serum IL-6 in the MS group was higher than that in the non-MS group, and the difference was statistically significant (P ＜ 0.05). The serum IL-6 levels of the patients were negatively correlated with the RBANS attention score (r = -0.16, P ＜ 0.05). Conclusion The increase of IL-6 caused by MS caused by Olanzapine may cause secondary cognitive impairment in patients with schizophrenia.

Key words： Schizophrenia Interleukin-6 Metabolic syndrome Cognitive function Olanzapine

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LU Weihong1 WEN Wanjun2 WANG Weiping3 TANG Wei4 ZHANG Yi1 ZHANG Chen1▲

Cite this article:

LU Weihong1 WEN Wanjun2 WANG Weiping3 TANG Wei4 ZHANG Yi1 ZHANG Chen1▲. Relationship between metabolic syndrome caused by Olanzapine and serum IL-6 level and cognitive function[J]. 中国医药导报, 2020, 17(31): 103-106.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I31/103

[1] Vandenberghe F，Najar-Giroud A，Holzer L，et al. Second-Generation Antipsychotics in Adolescent Psychiatric Patients：Metabolic Effects and Impact of an Early Weight Change to Predict Longer Term Weight Gain [J]. J Child Adolesc Psychopharmacol，2018，28（4）：258-265.
[2] 高慧，姚培芬，盛嘉玲，等.长期服用奥氮平精神分裂症患者稳定期认知功能和代谢综合征的关系[J].临床精神医学杂志，2017，27（5）：293-296.
[3] Ribeiro-Santos R，de Campos-Carli SM，Ferretjans R，et al. The association of cognitive performance and IL-6 levels in schizophrenia is influenced by age and antipsychotic treatment [J]. Nord J Psychiatry，2020，74131：187-193.
[4] Vancampfort D，Stubbs B，Mitchell AJ，et al. Risk of met-abolic syndrome and its components in people with schizo-phrenia and related psychotic disorders，bipolar disorder and major depressive disorder：a systematic review and meta-analysis [J]. World Psychiatry，2015，14（3）：339-347.
[5] American Psychiatric Association. Diagnostic and statistical manual of mental disorders [M]. 4th ed. Washington：American Psychiatric Association，1994.
[6] Grundy SM，Cleeman JI，Daniels SR，et al. Diagnosis and management of the metabolic syndrome：an American Heart Association/National Heart，Lung，and Blood Institute scientific statement：Executive Summary [J]. Crit Pathw Cardiol，2005，4（4）：198-203.
[7] Randolph C，Tierney MC，Mohr E，et al. The Repeatable Battery for the Assessment of Neuropsychological Status （RBANS）：preliminary clinical validity [J]. J Clin Exp Neuropsychol，1998，20（3）：310-319.
[8] Fang X，Wang Y，Chen Y，et al. Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics [J]. Neuropsychiatr Dis Treat，2019，15：2161-2170.
[9] Xu F，Fan W，Wang W，et al. Effects of omega-3 fatty acids on metabolic syndrome in patients with schizophrenia：a12-week randomized placebo-controlled trial [J]. Psychopharmacology （Berl），2019，236（4）：1273-1279.
[10] Zhang Y，Fang X，Fan W，et al. Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia：12-week results from a prospective longitudinal study [J]. Psychopharmacology （Berl），2018，235（4）：1191-1198.
[11] Zhang C，Fang X，Yao P，et al. Metabolic adverse effects of olanzapine on cognitive dysfunction：A possible relationship between BDNF and TNF-alpha [J]. Psychoneuroendocrinology，2017，81：138-143.
[12] Zhang C，Chen MJ，Wu GJ，et al. Effectiveness of Antipsychotic Drugs for 24-Month Maintenance Treatment in First-Episode Schizophrenia：Evidence From a Community-Based “Real-World” Study [J]. J Clin Psychiatry，2016，77（11）：e1460-e1466.
[13] Chen Y，Hua S，Wang W，et al. A comprehensive analysis of GSK3B variation for schizophrenia in Han Chinese individuals [J]. Asian J Psychiatr，2020，47：101832.
[14] Zhang Y，Fang X，Fan W，et al. Interaction between BDNF and TNF-α genes in schizophrenia [J]. Psychoneuroendocrinology，2018，89：1-6.
[15] Harada E，Morizono T，Kanno T，et al. Medicinal Mushroom，Grifola gargal （Agaricomycetes），Lowers Triglyceride in Animal Models of Obesity and Diabetes and in Adults with Prediabetes [J]. Int J Med Mushrooms，2020，22（1）：79-91.
[16] Kwaifa IK，Bahari H，Yong YK，et al. Endothelial Dysfunction in Obesity-Induced Inflammation：Molecular Mechanisms and Clinical Implications [J]. Biomolecules，2020，10（2）：291.
[17] Fernandes J，Fialho M，Santos R，et al. Is olive oil good for you? A systematic review and meta-analysis on anti-inflammatory benefits from regular dietary intake [J]. Nutrition，2020，69：110559.
[18] Sherrier M，Li H. The impact of keto-adaptation on exercise performance and the role of metabolic-regulating cytokines [J]. Am J Clin Nutr，2019，110（3）：562-557.
[19] Van Guilder GP，Hoetzer GL，Greiner JJ，et al. Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults [J]. Obesity （Silver Spring），2006，14（12）：2127-2131.
[20] Tenorio-Jiménez C，Martínez-Ramírez MJ，Gil ?魣，et al. Effects of Probiotics on Metabolic Syndrome：A Systematic Review of Randomized Clinical Trials [J]. Nutrients，2020，12（1）：124.
[21] Srivastava MC，Srivastava R，Verma PK，et al. Metabolic syndrome and periodontal disease：An overview for physicians [J]. J Family Med Prim Care，2019，8（11）：3492-3495.
[22] Qian Y，Lei G，Wen L. Brain-specific deletion of TRIM13 promotes metabolic stress-triggered insulin resistance，glucose intolerance，and neuroinflammation [J]. Biochem Biophys Res Commun，2020，527（1）：138-145.
[23] Liu C，Zhao S，Zhu C，et al. Ergosterol ameliorates renal inflammatory responses in mice model of diabetic nephropathy [J]. Biomed Pharmacother，2020，128：110252.
[24] Brown JA，Sherrod SD，Goodwin CR，et al. Metabolic consequences of interleukin-6 challenge in developing neurons and astroglia [J]. J Neuroinflammation，2014，11：183.
[25] Borovcanin MM，Jovanovic I，Radosavljevic G，et al. Interleukin-6 in Schizophrenia-Is There a Therapeutic Relevance? [J]. Front Psychiatry，2017，8：221.